Sanofi has announced that it will lower the list price of its insulin drug, Lantus, by 78 percent and will set a $35 cap on out-of-pocket costs for all patients.
The price change and cap will go into effect starting January 1, 2024. They follow a series of moves made last year to lower the price of diabetes medicine, including the launch of an unbranded version of Lantus and a $35 cap for uninsured patients.
Yet, Olivier Bogillot, head of U.S. general medicines at Sanofi, said "the health system was unable to take advantage of it due to its inherent structural challenges."
“Sanofi believes that no one should struggle to pay for their insulin and we are proud of our continued actions to improve access and affordability for millions of patients for many years," he said. "Our decision to cut the list price of our lead insulin needs to be coupled with broader change to the overall system to actually drive savings for patients at the pharmacy counter.”
Sanofi will also cut the price of short-acting Apidra by 70 percent.
Mastercards's Chief Technology Officer Ed McLaughlin shows Cheddar News Senior Reporter Michelle Castillo what shoppers can expect in shopping technology.
Almost a week after the Apple faithful collectively gasped at the first evidence that the iPhone’s red “end call” button might soon be vacating its center position to take up residence one column to the right, it looks like it might have been mostly a false alarm.
Meta is under scrutiny for the way it has moderated reproductive health content. Women's health advocates say the social media giant has allowed male health content to flow more freely than content geared toward women and gender diversity.
